# Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

> **NCT07653477** · PHASE3 · RECRUITING · sponsor: **The United Bio-Technology (Hengqin) Co., Ltd.** · enrollment: 956 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** UBT251 Injection 2.0 mg group
- **DRUG:** UBT251 Injection 4.0 mg group
- **DRUG:** UBT251 Injection 6.0 mg group
- **DRUG:** Semaglutide Injection

## Key facts

- **NCT ID:** NCT07653477
- **Lead sponsor:** The United Bio-Technology (Hengqin) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-07
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-02-29
- **Target enrollment:** 956 (ESTIMATED)
- **Last updated:** 2026-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07653477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07653477, "Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07653477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*